Increased longevity of HIV-infected individuals due to expanding pharmacological research allows a longer period of time for mood disorders to come to medical attention. A longer period of time exists in which the treatment of depression can make a difference in the quality of life, function, and course of HIV infection. Many HIV-related symptoms and concurrent treatment regimens can complicate the choices made regarding mood disorder treatments. Certain HIV/AIDS patients are at greater risk for developing depression, such as those with substance abuse/dependence. Differentiation between the clinical presentation of depression in the general population versus the HIV/AIDS population is important. Although differentiating between symptoms of depression, somatic complaints, and cognitive deficits may be difficult, specific symptoms in HIV-infected individuals prevail. Substantial evidence suggests that antidepressant therapy and psychotherapy are effective in most HIV-positive patients with major depression. One of the greatest difficulties in drug selection for the HIV-infected population is the avoidance of clinically significant drug-drug interactions between antidepressants and antiretrovirals. Evaluating the tolerability of antidepressant medications is also an important factor of effective treatment. This article attempts to clarify all the aforementioned issues pertaining to treatment choices in HIVinfected individuals suffering from depression.
1.Chesney MA, Folkman S.Psychological impact of HIV disease and implications for intervention.Psych Clin North Am.1994; 17:163–182.
2.
2.Zegans LS, Gerhard AL, Coates TJ. Psychotherapies for the person with HIV disease. Psych Clin North Am.1994; 17:149–162.
3.
3.Ostrow DG. Substance abuse and HIV infection. Psych Clin North Am.1994; 17:69–89.
4.
4.Patterson TL, Semple SJ, Temoshok LR, et al. Stress and depressive symptoms prospectively predict immune change among HIV-seropositive men. Psychiatry.1995; 58:299–312.
5.
5.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed.Washington, DC: American Psychiatric Association; 1994.
6.
6.Holloway RG, Kieburtz KD. Neurological manifestations of HIV infection.In Principles and Practice of Infectious Disease, 5th ed.Philadelphia, PA: Churchill Livingstone; 2000.
7.
7.Rabkin JG, Wagner G, Rabkin R. Prevalence and treatment of depressive disorders in HIV illness. Medscape Mental Health(serial online).1997 Mar 21.
8.
8.Kelly B, Raphael B, Judd F, et al. Psychiatric disorder in HIV infection. Aust N Z J Psychiatry.1998; 32:441–453.
9.
9.Perkins DO, Stern RA, Golden RN, et al. Mood disorders in HIV infection: prevalence and risk factors in a non-epicenter of the AIDS epidemic. Am J Psychiatry.1994; 151:233–236.
10.
10.McDaniel JS, Fowlie E, Summerville MB, et al. An assessment of rates of psychiatric morbidity and functioning in HIV disease. Gen Hosp Psychiatry.1995; 17:346–352.
11.
11.Brown GR, Rundell JR. A prospective study of psychiatric aspects of early HIV disease in women. Gen Hosp Psychiatry.1993; 15:139–147.
12.
12.Brown GR, Rundell JR, McManis SE, et al. Prevalence of psychiatric disorders in early stages of HIV infection. Psychosom Med.1992; 54:588–601.
13.
13.Leserman J, Petitto JM, Perkins DO, et al. Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus–infected men. Arch Gen Psychiatry.1997; 54:279–285.
14.
14.Burack JH, Barrett DC, Stall RD, et al. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA.1993; 270(21):2568–2573.
15.
15.Mayne TJ, Vittinghoff E, Chesney MA, et al. Depressive affect and survival among gay and bisexual men infected with HIV. Arch Intern Med.1996; 156:2233–2238.
16.
16.Leserman J, Jackson ED, Petitto JM, et al. Progression to AIDS: the effects of stress, depressive symptoms, and social support. Psychosom Med.1999; 61:397–406.
17.
17.Vedhara K, Schifitto G, McDermott M, et al. Disease progression in HIV-positive women with moderate to severe immunosuppression: the role of depression. Behav Med.1999; 25:43–47.
18.
18.Hintz S, Kuck J, Peterkin J, et al. Depression in the context of human immunodeficiency virus infection: implications for treatment. J Clin Psych.1990; 51:497–501.
19.
19.Rabkin JG, Goetz RR, Remien RH, et al. Stability of mood despite HIV illness progression in a group of homosexual men. Am J Psychiatry.1997; 154(2):231–238.
20.
20.Maj M, Janssen R, Starace F, et al. WHO Neuropsychiatric AIDS Study, cross sectional phase I.Study design and psychiatric findings. Arch Gen Psychiatry.1994; 51:39–49.
21.
21.Stern Y, Marder K, Bell K, et al. Multidisciplinary baseline assessment of homosexual men with and without human immunodeficiency virus infection III: neurological and neuropsychological findings. Arch Gen Psychiatry.1991; 48:131–138.
22.
22.Butler K.Psychiatric side effects from medical drugs. Pharmacy News.2000; 30(1):1–40.
23.
23.Evans DL, Staab J, Ward H, et al. Depression in the medically ill.Management considerations. Depress Anxiety.1996/97; 4:199–208.
24.
24.Perkins DO, Leserman J, Stern RA, et al. Somatic symptoms and HIV infection: relationship to depressive symptoms and indicators of HIV disease. Am J Psychiatry.1995; 152(12):1776–1781.
25.
25.Fukunishi I, Matsumoto T, Masayoshi N, et al. Somatic complaints associated with depressive symptomsin HIV-positive patients. Psychother Psychosom.1997; 66:248–251.
26.
26.Elliott AJ, Roy-Byrne PP. Major depressive disorder and HIV-1 infection: a review of treatment trials. Sem in Clin Neuropsychiatry.1998; 3(2):137–150.
27.
27.Penzak SR, Reddy YS, Grimsley SR. Depression in patients with HIV infection. Am J Health-Syst Pharm.2000; 57:376–388.
28.
28.Rabkin JG, Rabkin R, Harrison W, et al. Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry.1994; 151:516–523.
29.
29.Elliot AJ, Uldall KK, Bergam K, et al. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry.1998; 155:367–372.
30.
30.Markowitz JC, Kocsis JH, Fishman B, et al. Treatment of depressive symptoms in human immunodeficieny virus–positive patients. Arch Gen Psychiatry.1998; 55:452–457.
31.
31.Fernandez F, Levy JK, Samley HR, et al. Effects of methylphenidate in HIV-related depression: a comparative trial with desipramine. Int J Psychiatry Med.1995; 25:53–67.
32.
32.Rabkin JG, Harrison WM. Effect of imipramine on depression and immune status in a sample of men with HIV infection. Am J Psychiatry.1990; 147:495–497.
33.
33.Zisood S, Peterkin J, Goggin KJ, et al. Treatment of major depression in HIV-seropositive men. J Clin Psychiatry.1998; 59:217-224.
34.
34.Rabkin JG, Wagner GJ, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry.1999; 156:101-107.
35.
35.Targ EF, Karasic DH, Diefenbach PN, et al. Structured group therapy and fluoxetine to treat depression in HIV-positive persons. Psychosomatics.1994; 35:132–137.
36.
36.Rabkin JG, Rabkin R, Wagner G. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. J Clin Psychiatry.1994; 55:92–97.
37.
37.Levine S, Anderson D, Bystritsky A, et al. A report of eight HIV-seropositive patients with major depression responding to fluoxetine. J Acquir Immune Defic Syndr.1990; 3:1074–1077.
38.
38.Judd FK, Mijch AM, Cockram A. Fluoxetine treatment of depressed patients with HIV infection. Aust N Z J Psychiatry.1995; 29:433–436.
39.
39.Ferrando SJ, Goldman JD, Charness WE. Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS. Gen Hosp Psychiatry.1997; 19:89–97.
40.
40.Elliot AJ, Russo J, Bergam K, et al. Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. J Clin Psychiatry.1999; 60:226–231.
41.
41.Rabkin JG, Wagner G, Rabkin R. Effects of sertraline on mood and immune status in patients with major depression and HIV illness: an open trial. J Clin Psychiatry.1994; 55:433–439.
42.
42.Grassi B, Gambini O, Scarone S.Notes on the use of fluvoxamine as treatment of depression in HIV-1 infected subjects. Pharmacopsychiatry.1995; 28:93–94.
43.
43.Penzak SR, Reddy YS, Grimsley SR. Depression in patients with HIV infection. Am J Health-Syst Pharm.2000; 57:376–388.
44.
44.Elliott AJ, Roy-Byrne PP. Major depressive disorder and HIV-1 infection: a review of treatment trials. Sem in Clin Neuropsychiatry.1998; 3(2):137–150.
45.
45.Tseng AL, Foisy MM. Significant interactions with new antiretrovirals and psychotropic drugs. Ann Pharmacotherapy.1999; 33:461–473.
46.
46.Michalets EL. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy.1998; 18:84–112.
47.
47.Ereshefsky L, Riesenman C, Francis LamYW. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. J Clin Psych.1996; 57(suppl 8):17–25.
48.
48.Ferando S, Goggin K, Sewell M, et al. Substance use disorders in gay/bisexual men with HIV and AIDS. American Journal on Addictions.1998; 7:51–60.
49.
49.McGrath PJ, Nunes EV, Quitkin FM. Current concepts in the treatment of depression in alcoholdependent patients. Psychiatr Clin North Amer.2000; 23:695–711.
50.
50.Miller NS. Prevalence and treatment models for addiction in psychiatric populations. Psychiatric Annals.1994; 24:399–406.
51.
51.Brady KT, Roberts JM. The pharmacotherapy of dual diagnosis. Psychiatric Annals.1995; 25:344–352.
52.
52.Project MATCH Research Group. Matching alcoholism treatments to client heterogeneity: Project MATCH three-year drinking outcomes. Alcohol Clin Exp Res.1998; 22:1303–1311.
